Increase of serum cyclophilin C levels in the follow-up of coronary artery disease: A biomarker and possible clinical predictor




Jeremías Bayón, Department of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain
Amparo Alfonso, Department of Pharmacology, School of Veterinary, Universidad de Santiago de Compostela, Lugo, Spain
Melisa Santás-Álvarez, Department of Cardiology, Hospital Universitario Lucus Augusti (HULA), Lugo, Spain
Eva Alonso, Department of Pharmacology, School of Veterinary, Universidad de Santiago de Compostela; Santiago de Compostela Health Research Institute Foundation (FIDIS), Hospital Universitario Lucus Augusti. Lugo, Spain
Ana Testa-Fernández, Department of Cardiology, Hospital Universitario Lucus Augusti (HULA), Lugo, Spain
Ramón Ríos-Vázquez, Department of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain
Raymundo Ocaranza-Sánchez, Department of Cardiology, Hospital Universitario Lucus Augusti (HULA), Lugo, Spain
Rosa A. Abellás-Sequeiros , Unidad de Cardiología Intervencionista. Hospital Universitario Lucus Augusti, Lugo, España
Juliana Elices-Teja, Department of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain
Luis Botana, Department of Pharmacology, School of Veterinary, Universidad de Santiago de Compostela, Lugo, Spain
Carlos González-Juanatey, Department of Cardiology, Hospital Universitario Lucus Augusti (HULA), Lugo, Spain


Objective: This study is aimed at investigating the changes in serum CypC levels and their relationship with cardiovascular events at 12 months of follow-up in coronary artery disease (CAD) patients. Methods: The study included a total of 125 subjects (40 patients with acute CAD, 40 patients with chronic CAD, and 45 control volunteers) and we analyzed plasma CypC levels from baseline to 6 and 12 months for a better understanding of its behavior in atherosclerosis. Results: Serum CypC levels were shown to be gradually increased in CAD patients (30.63 pg/mL ± 3.77 at baseline, 38.70 pg/mL ± 6.41 at 6 months [p = 0.25], and 47.27 pg/mL ± 5.65 at 12 months [p = 0.007]). In addition, serum CypC levels during the follow-up were a significant predictor of CAD (c-statistic 0.76 at 6 months and 0.89 at 12 months; p < 0.001). Despite it, there was no significant association between CypC and cardiovascular events, but serum CypC levels tended to be higher in patients suffering cardiovascular events during the follow-up (29.02 pg/mL ± 6.39 vs. 79.96 pg/mL ± 22.18; p = 0.029). In this regard, plasma levels of high-sensitivity C-reactive protein (hsCRP) > 2.3 mg/L plus NT-proBNP > 300 pg/mL together were significant predictors of cardiovascular events during the follow-up in CAD patients with CypC levels >17.5 pg/mL (p = 0.048). Conclusions: Taken together, our results suggest that serum CypC levels increase during the follow-up in CAD patients and could be a novel biomarker with a possible prognostic value in combination with hsCRP and NT-proBNP.



Palabras clave: Coronary artery disease. Inflammation. Cyclophilin. Biomarkers.